An Abbott Laboratories processing plant in Sturgis, Mich being investigated for cases of infant illness is being allowed to release some product that was processed before it was shut down.
Certain goods designed for infants and people with specific medical issues will be given out for free.
Abbott officials claimed they're doing it at the FDA's request to help with shortages of these specialty feeding items.
After a recall of Similac infant formula and other products in February, the Sturgis plant was forced to shut down. Cronobacter bacteria had infected many infants, one of whom died; cronobacter was identified in their systems and the formula they had drunk. Cronobacter bacteria were discovered in the factory during an inspection.
However, further examination revealed that the cronobacter strain that caused the infections was not the same as the one detected in the plant and that no food-contact surfaces had been contaminated.
On a case-by-case basis, Abbott is issuing cases of a nutrition supplement for people with uncommon metabolic diseases and others. The corporation stated that it is doing so at the FDA's request to assist reduce shortages.


Gold and Silver Prices Slide as Dollar Strength and Easing Tensions Weigh on Metals
FDA Fast-Track Drug Reviews Delayed Over Safety and Efficacy Concerns
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Silver Prices Plunge in Asian Trade as Dollar Strength Triggers Fresh Precious Metals Sell-Off
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
South Korea’s Weak Won Struggles as Retail Investors Pour Money Into U.S. Stocks
U.S. Stock Futures Slide as Tech Rout Deepens on Amazon Capex Shock
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment
Oil Prices Slide on US-Iran Talks, Dollar Strength and Profit-Taking Pressure
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 



